Larsen RH, Kolstad A, Fosså A, Repetto-Llamazares A, Smerud KT, Illidge T, Bruland ØS(2026) A Phase II Study of 177Lu-Lilotomab Satetraxetan, a CD37 Antibody-Radionuclide Conjugate, as Third- or Later-Line Treatment of Rituximab-Refractory Follicular B-Cell Lymphoma Patients Pharmaceuticals (Basel), 19(2) DOI 10.3390/ph19020250, PubMed 41754790
Lia K, Galleberg RB, Rostoft S, Jørgensen RRK, Smeland KB, Hjermstad MJ, Sørland K, Fagerli UM, Bø IB, Johansen J, Bhargava S, Kiserud CE, Fosså A(2026) Self-reported late effects, daily functioning, and health-related quality of life in older Hodgkin lymphoma survivors - a national population-based cross-sectional survey Leuk Lymphoma, 1-11(in press) DOI 10.1080/10428194.2026.2633180, PubMed 41761714
Publications 2025
Bouska A, Zhang W, Sharma S, Holte H, Shah RA, Lone WG, Soma MA, Yang R, Liu X, Mehmood S, Chawla RS, Cappelli LV, Fiore D, Gong Q, Heavican-Foral TB, Cannatella JJ, Amador C, Arif A, Smith LM, Lim ST, Ong CK, Feldman AL, Du MQ, Perry AM, de Leval Let al.(2025) Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma Am J Hematol, 100(9), 1486-1501 DOI 10.1002/ajh.27736, PubMed 40510016
